Tango Therapeutics Inc

NASDAQ TNGX
$6.94 0.11 1.61%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23.75 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
151.11M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
95.50M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
110.30M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
124.60 %

Upcoming events Tango Therapeutics Inc

All events
No upcoming events scheduled

Stock chart Tango Therapeutics Inc

Stock analysis Tango Therapeutics Inc

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.14 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.69 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.78 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.45 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-79.32 -50.00

Price change Tango Therapeutics Inc per year

1.10$ 10.50$
Min Max

Summary analysis Tango Therapeutics Inc

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Tango Therapeutics Inc

Revenue and net income Tango Therapeutics Inc

All parameters

About company Tango Therapeutics Inc

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Address:
201 Brookline Avenue, Boston, MA, United States, 02215
Company name: Tango Therapeutics Inc
Issuer ticker: TNGX
ISIN: US87583X1090
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2020-09-03
Sector: Healthcare
Industry: Biotechnology
Site: https://www.tangotx.com